China Tracker - Details for China Pharma Holdings (CPHI)

 China Pharma Holdings
Shares Outstanding (MRQ): 43.40 mill 
New Shares / Dilution (TTM): 0.00 mill0.00%
New Shares / Dilution (since Dec 31, 2008): 1.13 mill2.66% 
Cash (MRQ): 3.80 mill34.91%
Account Receivables (MRQ): 63.99 mill587.37%
Account Receivables (Q/Q): + 2.04 mill3.30% 
Long-Term Debt (MRQ): 0.33 mill3.02%
Revenue Growth (Q/Q): -24.42% 
Revenue Growth (Y/Y): 19.98% 
Net Income Growth (Q/Q): -37.17% 
Net Income Growth (Y/Y): 1.60% 
EPS Growth (Y/Y): 1.60% 
Net Margin (Q/Q): 24.5% (29.4%)-5.00% 
Net Margin (Y/Y): 24.5% (28.9%)-4.40% 
EPS | P/E (2 MRQ Projection): $0.530.47
CFPS | P/CF (2 MRQ Projection): $0.141.75
Price/Sales (2 MRQ Projection): 0.13
Price/Book (MRQ): 0.09
Auditor: Hansen, Barnett and Maxwell
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2010-10-31): $0.500.50
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2005-10-19 
Uplisting to Senior Exchange: on 2009-09-30 at $3.03 (-91.72% since Uplisting)

 Business Outlook

In the second half of 2011, we expect to add new higher-margin revenue streams with our upcoming new products, which should help offset some of the margin pressure coming from the more competitive pricing due to government reform policies. Overall we are still very optimistic that we have the right mix of products and pipeline opportunities to position China Pharma to benefit from China's healthcare reform program.

(Source: PR Newswire, 2011-08-11)

In 2011, we anticipate adding new higher-margin revenue streams to our upcoming new products, which should help offset pockets of margin pressure coming from higher raw material costs and more competitive pricing due to government reform policies. Overall we are very optimistic that we have the right mix of products and pipeline opportunities to position China Pharma to benefit from China's unprecedented $124 billion healthcare reform program. We believe our success in 2011 and beyond will be defined by our high-quality manufacturing facilities and promising pipeline, strong distribution relationships, and commercialization expertise.

(Source: PR Newswire, 2011-05-11)

In 2011, we anticipate adding new higher-margin revenue streams to our upcoming new products, which should help offset pockets of margin pressure coming from higher raw material costs and more competitive pricing due to government reform policies. Overall we are very optimistic that we have the right mix of products and pipeline opportunities to position China Pharma to benefit from China's unprecedented $124 billion healthcare reform program. We believe our success in 2011 and beyond will be defined by our high-quality manufacturing facilities and promising pipeline, strong distribution relationships, and commercialization expertise.

(Source: PR Newswire, 2011-03-03)

    see all Business Outlook notes

 Analyst Coverage (show more)
2011-08-12Roth CapitalReiterationBuy$4.50
2011-07-25Rodman & RenshawDowngradeTerminatedn/a
2011-06-10Ladenburg ThalmannDowngradeTerminatedn/a
2011-05-11Roth CapitalReiterationBuy$5.00
2011-03-09Roth CapitalReiterationBuy$5.00

CPHI is currently followed by 3 analysts. 2 give the stock a positive rating, 1 rate it neutral and 0 give it a negative rating.


    see all Analyst Ratings

 Recent Financings
2009-12-28Filing$50.00 mill--

 Investor Presentations
2010-02-01 (PDF)   DOWNLOAD (right click, save as)
CPHI
Healthcare & Drugs
SCORE
10
READ: Score Cards Explained
SAFETY/RISK SCORE
HIGH RISK
DETAILS: Safety/Risk Model for CPHI
Current Price:  $0.25
F10k Day (2006-05-09): -83.81%$1.55
2009 Close: -93.49%$3.85
2010 Close: -91.72%$3.03
2011 Close: -62.54%$0.67
High (2012-02-09): -71.15%$0.87
Low (2012-05-17): 19.52%$0.21
Exchange: ASE
Market Capitalization: 10.89 mill
Total Shares: 43.40 mill
Float: 21,937,000.00 mill
Avg Volume: 71.80 k
Short Interest: 807.10 k
Short Ratio: 4.63%11.2 d
Last Quarter: 2011-03-31
Revenue (MRQ): 18.12 mill
Net Income (MRQ): 4.44 mill
Op. Cash Flow (MRQ): 1.39 mill
all financial data provided without warranty